Cargando…

Interleukin-1α enhances the aggressive behavior of pancreatic cancer cells by regulating the α(6)β(1)-integrin and urokinase plasminogen activator receptor expression

BACKGROUND: In human pancreatic cancer progression, the α(6)β(1)-integrin is expressed on cancer cell surface during invasion and metastasis formation. In this study, we investigated whether interleukin (IL)-1α induces the alterations of integrin subunits and urokinase plasminogen activator/urokinas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sawai, Hirozumi, Okada, Yuji, Funahashi, Hitoshi, Matsuo, Yoichi, Takahashi, Hiroki, Takeyama, Hiromitsu, Manabe, Tadao
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1388210/ https://www.ncbi.nlm.nih.gov/pubmed/16504015 http://dx.doi.org/10.1186/1471-2121-7-8

Ejemplares similares

Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation
por: Sawai, Hirozumi, et al.
Publicado: (2005)

Reactive Lymphoid Hyperplasia of the liver in a patient with colon cancer: report of two cases
por: Takahashi, Hiroki, et al.
Publicado: (2006)

The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells
por: Yasuda, Akira, et al.
Publicado: (2006)

Successful paclitaxel-based chemotherapy for an alpha-fetoprotein-producing gastric cancer patient with multiple liver metastases
por: Takeyama, Hiromitsu, et al.
Publicado: (2007)

Solid variant of serous cystadenoma of the pancreas
por: Yasuda, Akira, et al.
Publicado: (2011)

Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival
por: Sawai, Hirozumi, et al.
Publicado: (2008)

In silico docking of urokinase plasminogen activator and integrins
por: Degryse, Bernard, et al.
Publicado: (2008)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Immunohistochemical localization of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and α2-antiplasmin in human corneal perforation: a case report
por: Sugioka, Koji, et al.
Publicado: (2012)

Ascites induces modulation of α6β1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma
por: Ahmed, N, et al.
Publicado: (2005)

Regulation of α5β1 integrin conformation and function by urokinase receptor binding
por: Wei, Ying, et al.
Publicado: (2005)

Granulocyte-colony stimulating factor producing rectal cancer
por: Takahashi, Hiroki, et al.
Publicado: (2008)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis
por: Lee, Ji-Hye, et al.
Publicado: (2014)

Successful combination chemotherapy with irinotecan hydrochloride and cisplatin for primary gastric small cell carcinoma: report of a case
por: Funahashi, Hitoshi, et al.
Publicado: (2013)

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
por: Knoop, A., et al.
Publicado: (1998)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
por: Zhu, Ran, et al.
Publicado: (2022)

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
por: Gupta, Kamlesh K., et al.
Publicado: (2017)

Is the Urokinase Plasminogen Activator/Plasminogen Activator Inhibitor-1 Ratio a Marker of Sonographic Septations in Pleural Infection?
por: Yasuma, Taro, et al.
Publicado: (2022)

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
Publicado: (1987)

Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse
Publicado: (1984)

The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type
Publicado: (1986)

Urokinase plasminogen activator receptor, beta 2-integrins, and Src- kinases within a single receptor complex of human monocytes
Publicado: (1995)

A specific plasminogen activator inhibitor‐1 antagonist derived from inactivated urokinase
por: Gong, Lihu, et al.
Publicado: (2016)

Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator
por: Heynekamp, Justin J, et al.
Publicado: (2006)

Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts
por: Chao, Shih-Chun, et al.
Publicado: (2011)

Urokinase-type plasminogen activator receptor in IgA nephropathy
por: Ahn, Shin-Young, et al.
Publicado: (2014)

Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma
por: Ierodiakonou, Despo, et al.
Publicado: (2016)

Urokinase-type Plasminogen Activator Induces Neurorepair in the Ischemic Brain
por: Merino, Paola, et al.
Publicado: (2018)

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
por: Lampelj, Maja, et al.
Publicado: (2015)

Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK)
por: Santos, Nancy Dos, et al.
Publicado: (2007)

The Contribution of the Urokinase Plasminogen Activator and the Urokinase Receptor to Pleural and Parenchymal Lung Injury and Repair: A Narrative Review
por: Tucker, Torry A., et al.
Publicado: (2021)

Integrin α11β1 is expressed in breast cancer stroma and associates with aggressive tumor phenotypes
por: Smeland, Hilde Ytre‐Hauge, et al.
Publicado: (2019)

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994)

Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
por: Cantero, D., et al.
Publicado: (1997)

Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells
Publicado: (1987)

immunocytochemical localization of urokinase-type plasminogen activator in lewis lung carcinoma
por: Skriver, L, et al.
Publicado: (1984)

Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants
por: Haastrup, Eva, et al.
Publicado: (2014)

Urokinase-type plasminogen activator: a new target for male contraception?
por: Qin, Ying, et al.
Publicado: (2015)

Urokinase-Type Plasminogen Activator Deficiency Promotes Neoplasmatogenesis in the Colon of Mice()()()
por: Karamanavi, Elisavet, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gm2264c2gts08e7ujv60ig0miq